501.V2 variant

SARS-CoV-2 variants of concern pose a higher risk for hospitalisation and intensive care admission

Retrieved on: 
Saturday, May 1, 2021
Variants of SARS-CoV-2, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Companies, Dutch East India Company, Trade, Economy, 501.V2 variant

A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.

Key Points: 
  • A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.
  • The analysis of 19 995 VOC and 3 348 non-VOC cases suggests that the VOC pose a higher risk for developing severe diseases.
  • Compared to cases infected with a non-VOC virus, the risk for hospitalisation in B.1.1.7 cases was 1.7 times higher, while in B.1.351 it was 3.6 times higher and for P.1 it was 2.6 times higher.
  • This study also showed an increased risk of being admitted to intensive care by 2.3, 3.3 and 2.2 times higher for people infected by B.1.1.7, B.1.351 and P.1 respectively, compared to non-VOC cases.

Celltrion’s anti-COVID 19 monoclonal antibody treatment, regdanvimab (CT-P59), demonstrates neutralising effect against the South African variant (B.1.351)

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Clinical medicine, Variants of SARS-CoV-2, 501.V2 variant, COVID-19 pandemic in South Africa, Zoonoses, Monoclonal antibody, COVID-19, Severe acute respiratory syndrome coronavirus, P59

b'Celltrion Group today announced preliminary pre-clinical results for regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment, with data demonstrating that CT-P59 has a neutralising effect against the South African variant in an in vivo model.

Key Points: 
  • b'Celltrion Group today announced preliminary pre-clinical results for regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment, with data demonstrating that CT-P59 has a neutralising effect against the South African variant in an in vivo model.
  • The study demonstrated that CT-P59 treatment, at a clinically relevant dose, results in a significant reduction in viral load of SARS-CoV-2.
  • CT-P59 demonstrated reduction in the binding affinity against the receptor binding domain (RBD) in the three mutations (K417N, E484K and N501Y substitutions) of the South African variant.
  • In addition, CT-P59 showed a reduced susceptibility against the South African variant in a live virus and pseudo-virus assay in vitro study.

SARS-CoV-2 COVID Vaccine Market Demands, Growth, Size, Supply and Key Players are Pfizer, BioNTech, Moderna, AstraZeneca, Novovax, J&J and Others - ReportsnReports

Retrieved on: 
Tuesday, April 27, 2021
Medical research, Health sciences, Health, COVID-19 vaccine, BioNTech, CureVac, Pfizer, 501.V2 variant, CureVac COVID-19 vaccine

Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021.

Key Points: 
  • Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021.
  • Currently, Pfizer/BioNTech, Moderna, AstraZeneca, Gamelaya, J&J, Novavax, Sinovac and Curevac have developed the most prominent vaccines in the pipeline.
  • The B.1.1.7 strain contains numerous mutations in the spike region which give it a higher affinity to attach to human cells.
  • Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.\n"

SARS-CoV-2 COVID Vaccine Market Demands, Growth, Size, Supply and Key Players are Pfizer, BioNTech, Moderna, AstraZeneca, Novovax, J&J and Others - ReportsnReports

Retrieved on: 
Tuesday, April 27, 2021
Medical research, Health sciences, Health, COVID-19 vaccine, BioNTech, CureVac, Pfizer, 501.V2 variant, CureVac COVID-19 vaccine

Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021.

Key Points: 
  • Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021.
  • Currently, Pfizer/BioNTech, Moderna, AstraZeneca, Gamelaya, J&J, Novavax, Sinovac and Curevac have developed the most prominent vaccines in the pipeline.
  • The B.1.1.7 strain contains numerous mutations in the spike region which give it a higher affinity to attach to human cells.
  • Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.\n"

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Retrieved on: 
Monday, April 12, 2021
Articles, Variants of SARS-CoV-2, Health, Global health, Pandemics, Zoonoses, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, 501.V2 variant, Virus, Variant of concern

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points: 
  • The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
  • "Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
  • the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
  • Seegene continues to set new standards in MDx providing new, cost-effective innovations.\n'

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Retrieved on: 
Monday, April 12, 2021
Articles, Variants of SARS-CoV-2, Health, Occupational safety and health, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, COVID-19, 501.V2 variant, Pandemic, Variant of concern, COVID-20

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points: 
  • The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
  • "Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
  • the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
  • Seegene continues to set new standards in MDx providing new, cost-effective innovations.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/seegene-begins-exporting-its-lat...\n'

COVID-19 Antibody Tests For Variants Now Available Worldwide

Retrieved on: 
Monday, March 29, 2021
Coronaviridae, Sarbecovirus, SARS-CoV-2, Variants of SARS-CoV-2, Zoonoses, Occupational safety and health, Atypical pneumonias, COVID-19, 501.V2 variant, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7, Lineage P.1

(MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.

Key Points: 
  • (MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.
  • Variants of SARS-CoV-2 may evade immunity or increase transmission, increasing COVID-19 cases and potentially diminishing the impact of vaccines.MSD's new V-PLEX Serology Panels help scientists understand how SARS-CoV-2 variants respond to antibodies generated by vaccination or natural infection.
  • Jacob Wohlstadter, President and Chief Executive Officer, remarked, "The emergence of certain new SARS-CoV-2 variants presents a challenge to the worldwide effort to combat COVID-19.We are grateful to the many organizations studying and developing new vaccines for important variants.
  • "These new tests will accelerate the timelines for developing vaccines against variants," said James Wilbur, Chief Business Officer of MSD.

DGAP-News: CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

Retrieved on: 
Tuesday, March 23, 2021
SARS-CoV-2, Medical specialties, Variants of SARS-CoV-2, Medicine, COVID-19 vaccines, Clinical trials, Zoonoses, 501.V2 variant, COVID-19 pandemic in South Africa, CureVac COVID-19 vaccine, Vaccine, Middle East respiratory syndrome–related coronavirus, CVnCoV, CureVac

Consistent with available variant studies, the neutralization capacity of robust antibody titers was shown to be impacted by the B.1.351 variant compared to the original strain.

Key Points: 
  • Consistent with available variant studies, the neutralization capacity of robust antibody titers was shown to be impacted by the B.1.351 variant compared to the original strain.
  • The full manuscript of the preclinical data is available on the bioRxiv preprint server.
  • Vaccination resulted in robust antibody responses and complete protection (100% survival) against the original SARS-CoV-2 strain and also B.1.351 (variant strain first identified in South Africa) challenge infections.
  • The company entered into a collaboration agreement with Bayer in January 2021 with regards to CureVac's current vaccine candidate CVnCoV.

Article - Covid-19 variants: state of play and impact on vaccination in the EU

Retrieved on: 
Wednesday, March 17, 2021
Health, Articles, SARS-CoV-2, Variants of SARS-CoV-2, Occupational safety and health, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Coronavirus disease, Vaccination, Vaccine, COVID-19 pandemic, 501.V2 variant

As part of Parliaments continued close monitoring of the EUs vaccination strategy, members of the environment and public health committee heard fromrepresentatives from the European Centre for Disease Prevention and Control, the European Medicines Agency and the World Health Organization on the efficacy of vaccines against mutations of the Covid-19 virus.

Key Points: 
  • As part of Parliaments continued close monitoring of the EUs vaccination strategy, members of the environment and public health committee heard fromrepresentatives from the European Centre for Disease Prevention and Control, the European Medicines Agency and the World Health Organization on the efficacy of vaccines against mutations of the Covid-19 virus.
  • This was the latest in a string of hearings and events during which key players in the Covid-19 crisis are keeping MEPs updated on their work.
  • Three main variants in the EU

    Dr Bruno Ciancio, head of surveillance at the European Centre for Disease Prevention and Control, said there are currently three main variants of concern in the EU: the UK variant, the South African variant and the Brazilian variant.

  • Given the current knowledge of the variants, he said the centre's models predict that the current measures and vaccination strategy rolled out by the EU will still be effective, but stressed the importance of countries keeping track of variants and their spread.

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

Retrieved on: 
Tuesday, March 16, 2021
Research, Technology, Infectious diseases, Biotechnology, General Health, Pharmaceutical, Health, Data management, Science, Other Science, Coronaviridae, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, Coronavirus disease, Severe acute respiratory syndrome coronavirus 2, Lineage B.1.1.7, Severe acute respiratory syndrome coronavirus, 501.V2 variant, Lineage P.1, Variant, Severe acute respiratory syndrome, IPA’s PolyTope Platform., ImmunoPrecise Antibodies Ltd.

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.

Key Points: 
  • Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.
  • Results of the screening also indicate that identified antibodies retain the ability to bind to emerging SARS-CoV-2 variants including U.K. (B.1.1.7 lineage), S. African (B.1.351 lineage) and Brazilian (P.1 lineage) strains.
  • Researchers studying SARS-CoV-2, the virus that causes COVID-19, have indicated that global variants are more transmissible than the original strain.
  • The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date.